DTx Pharma: Developer of an RNA-based therapeutics designed to aid in personalized treatment across most therapeutic areas. The company's technology enables efficient delivery of nucleic acid drugs to tissues throughout the body, enabling healthcare providers to deliver oligos in vivo at therapeutically relevant doses that work in many cell types including neurons, endothelial and T cells. Their pipeline consists of novel therapeutic candidates to help patients with neuromuscular, muscle, and CNS diseases. DTx has raised more than $100M in combined investment from healthcare investors including RA Capital and Access Biotechnology, pharmaceutical companies such as Eli Lilly, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF).